Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LPCN
#3478
Lipocine Inc.
9.960
0
+4.73%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+4.73%
Mudança mensal
-0.10%
Mudança em 6 meses
+243.45%
Mudança anual
+243.45%
Fechamento anterior
9.510
0
Open
9.960
0
Bid
Ask
Low
9.960
0
High
9.960
0
Volume
6
Mercados
Ações
Cuidados de saúde
LPCN
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
5.19 M
5.19 M
5.21 M
5.32 M
5.35 M
—
Valuation ratios
Enterprise value
—
—
—
10.43 M
19.9 M
56.57 M
Price to earnings ratio
—
—
—
-0.91
—
—
Price to sales ratio
—
—
—
-5.29
2.36
14.68
Price to cash flow ratio
—
—
—
-1.27
-21.67
-31.05
Price to book ratio
—
—
—
0.74
1.26
1.91
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.83
-0.01
-0.29
-0.71
0
-0.33
Return on equity %
1.37
-0.01
-0.3
-0.8
0
-0.37
Return on invested capital %
1 968.06
197.11
-756.24
-4 024.13
-1 283.14
-4 761.62
Gross margin %
—
100
100
100
100
400
Operating margin %
—
19.49
-2 423.88
628.98
-10.31
-5 502.09
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
-3.93
-2 151.73
573.59
0.07
-5 071.33
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.85
8.26
20.34
8.69
14.75
51.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.41
0.01
-0.09
0.49
0.2
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.09
0
—
—
—
—
Long term debt to total equity ratio
0.15
0
—
—
—
—
Per share metrics
Operating cash flow per share
4.67
-0.86
-2.29
-2.25
-0.23
-0.96
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
6
8.73
6.22
4.18
3.99
13.82
Net current asset value per share
7.73
9.07
6.53
4.34
4.12
14.3
Tangible book value per share
4.68
8.91
6.82
3.87
3.87
13.27
Working capital per share
5.72
7.97
6.21
3.84
3.84
13.15
Book value per share
4.68
8.91
6.82
3.87
3.87
13.27
Notícias
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Lipocine completes patient visits in phase 3 trial for PPD treatment
H.C. Wainwright eleva preço-alvo das ações da Lipocine para US$ 15 com avanço em testes de PPD
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress
Lipocine completes enrollment in phase 3 trial for PPD treatment
Teste clínico do medicamento para DPP da Lipocine continua após revisão positiva de segurança
Lipocine’s PPD drug trial continues after positive safety review
Lipocine atinge 80% de recrutamento em teste de medicamento para depressão pós-parto
Lipocine reaches 80% enrollment in postpartum depression drug trial
Lipocine apresenta dados do candidato para epilepsia LPCN 2101 em reunião anual da AES
Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting
Lipocine reporta revisão positiva de segurança para tratamento de DPP em ensaio de fase 3